Ocugen(OCGN) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Research and development expenses for Q4 2025 were $10.7 million, up from $8.3 million in Q4 2024, indicating a 29% increase [22] - General and administrative expenses for Q4 2025 were $6.1 million, slightly down from $6.3 million in Q4 2024 [22] - The net loss per common share for Q4 2025 was $0.06, compared to a net loss of $0.05 per common share in Q4 2024 [22] - For the full year 2025, research and development expenses totaled $39.8 million, up from $32.1 million in 2024, reflecting a 24% increase [23] - General and administrative expenses for the full year 2025 were $27.6 million, compared to $26.7 million in 2024 [23] - The net loss per common share for the full year 2025 was $0.23, compared to $0.20 in 2024 [23] Business Line Data and Key Metrics Changes - Enrollment for the OCU400 Phase 3 liMeliGhT trial is complete, with top-line data expected in Q1 2027 [7] - The OCU400 trial enrolled 140 patients, with a primary endpoint of 12-month change in visual function assessed by LDNA [7] - OCU410ST is ahead of schedule, with top-line phase 2/3 data anticipated in Q2 2027 [10] - OCU410 demonstrated a 46% reduction in lesion growth at 12 months, significantly outperforming existing therapies [16] Market Data and Key Metrics Changes - The OCU400 program targets a broader patient population, addressing 98%-99% of retinitis pigmentosa patients, compared to existing therapies that target only 1%-2% [6] - OCU410 is positioned to address a significant market opportunity with approximately 2 million to 3 million geographic atrophy patients in the U.S. and Europe combined [15] Company Strategy and Development Direction - The company aims to file three Biologics License Applications (BLAs) in the next three years, with a focus on transitioning into a commercial stage company [4][18] - Ocugen is pursuing regional partnerships to maximize patient reach while retaining full commercial rights in larger markets [9] - The establishment of Ocucelix as a subsidiary for regenerative cell therapy assets indicates a strategic move to enhance shareholder value [18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in meeting timelines for clinical trials and regulatory submissions, emphasizing the transformative year of 2025 [4][21] - The company is focused on disciplined resource allocation as it advances toward late-stage development and potential commercialization [20] - Management highlighted the importance of upcoming milestones in 2026, including the completion of enrollment for OCU410ST and the initiation of phase 3 for OCU410 [18] Other Important Information - The company raised $22.5 million through an underwritten registered direct offering, extending its cash runway into Q4 2026 [23] - If $30 million in warrants from a prior raise are exercised, the cash runway could extend into Q2 2027 [24] Q&A Session Summary Question: Confidence in data turnaround for the liMeliGhT study - Management expressed confidence in meeting the timeline for releasing top-line data in Q1 2027 [26][28] Question: Modifications for the navigation assessment course - The proprietary mobility test used is validated and approved by the FDA, designed to capture real change in functional outcomes [28][29] Question: Impact of other therapies on OCU410ST opportunity - Management believes OCU410ST will set the standard of care, regardless of other therapies entering the market first [30][32] Question: FDA feedback on CMC part of the filing - CMC feedback is typically received after the final clinical module is filed, and management is planning to file this year [41] Question: Commercial value of the Ellipsoid Zone as an endpoint - The Ellipsoid Zone is gaining traction among clinicians and could provide meaningful information for commercial claims [46][48] Question: Characteristics of responders in the OCU410 program - Baseline characteristics were uniform across groups, with no unique criteria identified at this point [81]